Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation study

Nguyen Tran Nam Tien, Vu Ngan Binh, Pham Thi Thanh Ha, Dang Thi Ngoc Lan, Yong-Soon Cho, Nguyen Phuoc Long, Jae-Gook Shin, Nguyen Hoang Anh (Jr), Truong Anh Quan, Do Ngoc Tuan, Nguyen Khac Tiep, Pham The Thach, Nguyen Hoang Anh and Vu Dinh Hoa

PLOS ONE, 2024, vol. 19, issue 12, 1-15

Abstract: Objective: Meropenem degradation poses a challenge to continuous infusion (CI) implementation. However, data about the impact of degradation on the probability of target attainment (PTA) of meropenem has been limited. This study evaluated the stability of meropenem brands and the consequence of in-bottle degradation on PTA in different environmental scenarios. Method: Seven meropenem generic brands prepared at concentrations of 1 g/48mL and 2 g/48mL in saline were examined at 25, 30, and 37°C over 8 h. A linear mixed-effects model was used to estimate degradation rate constant and potential covariates. In-bottle stability data was subsequently integrated as input for a deterministic and stochastic simulation using a published population pharmacokinetic model of critical illness. The impact of the degradation on target attainment at 98%fT>MIC was assessed. Results: Time, temperature, and infusion concentration were factors affecting the stability of the meropenem solution for all products. The differences in the degradation of seven generics were subtle, so their simulated plasma concentrations were equal. Meropenem CI with 8 h renewal infusion achieved a higher PTA than the extended 3 h infusion, even at the highest degradation condition. The impact of meropenem degradation on PTA was minimal vis-à-vis the meropenem dose, patient’s renal function, and microbial susceptibility. Meropenem degradation reduced PTA by an observable magnitude in patients with augmented renal clearance and difficult-to-treat pathogens. Dose escalation up to 1.5–2g every 8 h could restore this reduction to the target 90% PTA. Conclusion: Meropenem CI with 8 h of renewal infusion, considering stability even in tropical areas, was feasible to maximize the efficacy to difficult-to-treat pathogens.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313764 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 13764&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0313764

DOI: 10.1371/journal.pone.0313764

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().